Harvard College

Other

Duke University

Donald M Coen

Robert L Martuza

Bryan R Cullen

Kristie Grove Bridges

David M Knipe

James Hogle

Scott Lokey

Carl Elkin

Harmon J Zuccola

Arianna Loregian

Jennifer Lin Umbach

Martha F Kramer

Beatrice D Pilger

Paul E Digard

Igor Jurak

Zuwen He

The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs and to methods of treatment based on the use of such agents.

Viral microRNA

Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.

Antiviral methods and compositions

A method for the structure-based identification and selection of inhibitors of processivity factor binding to protein is disclosed herein. Characterization of the protein/processivity factor interface is given. Methods for the structure-based inhibition of processivity factor binding to protein are also given. One embodiment includes a class of peptidomimetics that mimic helical portions of proteins. In addition, methods of treatment of various diseases are given, using the inhibitors of the invention.

Structure-based approach to design of inhibitors of protein-processivity factor interactions

Methods for determining inhibitors of protein interactions are provided. The method involves evaluation of potential inhibitors that can inhibit or prevent protein interactions. The method provides for high-throughput identification of novel therapeutics that can treat a disease or disorder by inhibiting protein interactions.

Fluorescence polarization method for determining viral inhibitors

The present invention is drawn to compositions and methods for selectively killing neoplastic cells. Altered viruses are utilized which are capable of replication in neoplastic cells while sparing surrounding normal tissue.

Viral mutant HSV mediated destruction of neoplastic cells

Soluble, enzymatically active CMV UL97 and methods of detecting inhibitors and enhancers of its ability to phosphorylate are disclosed.

UL97 fusion proteins and methods of use

An immunoassay for identifying an inhibitor of HSV DNA replication including providing a DNA polymerizing complex that includes two complex members, the complex members being HSV DNA polymerase and UL42, providing a potential inhibitor that inhibits the binding of HSV DNA polymerase to UL42, mixing the complex members in the presence of the potential inhibitor, and determining whether the potential inhibitor inhibits formation of the complex.

Growing community of inventors

Cambridge, MA, United States of America

Donald M Coen